Abstract
As the mean age of the general population increases, so does the need for reliable drugs for improving cognitive-memory disturbances in the elderly. Nootropic agents have been shown to improve memory and learning processes in animals and to be useful in patients with several types of senile or traumatic dementia. Pramiracetam, one of the newest nootropics to be launched, has exhibited good efficacy in both animal models of memory or learning impairment and patients with senile and presenile cognitive impairment, including dementia of the Alzheimer type. The exact mechanism of action of this drug has not been fully established, but clinical data on good efficacy, favorable pharmacokinetic properties and advantageous safety even on prolonged treatment make it a reasonable choice for treating attention and memory alterations in elderly patients with degenerative or vascular brain diseases.
| Language | English |
|---|---|
| Pages | 469-482 |
| Number of pages | 14 |
| Journal | Drugs of Today |
| Volume | 30 |
| Issue number | 6 |
| State | Published - 1994 |
Fingerprint
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology (medical)
- Pharmacology
Cite this
Pramiracetam : A nootropic agent with improved efficacy in patients with senile or presenile cognitive impairment. / Nappi, G.; Rabasseda, X.; Mealy, N.
In: Drugs of Today, Vol. 30, No. 6, 1994, p. 469-482.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pramiracetam
T2 - Drugs of Today
AU - Nappi,G.
AU - Rabasseda,X.
AU - Mealy,N.
PY - 1994
Y1 - 1994
N2 - As the mean age of the general population increases, so does the need for reliable drugs for improving cognitive-memory disturbances in the elderly. Nootropic agents have been shown to improve memory and learning processes in animals and to be useful in patients with several types of senile or traumatic dementia. Pramiracetam, one of the newest nootropics to be launched, has exhibited good efficacy in both animal models of memory or learning impairment and patients with senile and presenile cognitive impairment, including dementia of the Alzheimer type. The exact mechanism of action of this drug has not been fully established, but clinical data on good efficacy, favorable pharmacokinetic properties and advantageous safety even on prolonged treatment make it a reasonable choice for treating attention and memory alterations in elderly patients with degenerative or vascular brain diseases.
AB - As the mean age of the general population increases, so does the need for reliable drugs for improving cognitive-memory disturbances in the elderly. Nootropic agents have been shown to improve memory and learning processes in animals and to be useful in patients with several types of senile or traumatic dementia. Pramiracetam, one of the newest nootropics to be launched, has exhibited good efficacy in both animal models of memory or learning impairment and patients with senile and presenile cognitive impairment, including dementia of the Alzheimer type. The exact mechanism of action of this drug has not been fully established, but clinical data on good efficacy, favorable pharmacokinetic properties and advantageous safety even on prolonged treatment make it a reasonable choice for treating attention and memory alterations in elderly patients with degenerative or vascular brain diseases.
UR - http://www.scopus.com/inward/record.url?scp=0027970641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027970641&partnerID=8YFLogxK
M3 - Article
VL - 30
SP - 469
EP - 482
JO - Drugs of Today
JF - Drugs of Today
SN - 0025-7656
IS - 6
ER -